Health tech deals

  • SimCare AI raises $2m to scale clinical training with AI patients

    SimCare AI has announced US$2 million in seed funding to rethink clinical training from first principles: using AI patients to bypass regulatory constraints and certify clinical skills with far fewer patient interactions. The funding round was led by Y Combinator and Drive Capital, with participation from Harper Court Ventures Fund, Singularity Capital, Triple S Ventures, [...]

  • Fuse Vectors secures $5.2m to advance cell-free gene therapy technology

    Fuse Vectors has announced $5.2 million in pre-seed financing led by HCVC to revolutionise gene therapy development with its cell-free viral vector technology.  The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. Fuse Vectors aims to be the universal solution for AAV gene therapy development, delivering unmet patient [...]

  • We round up the latest investment news from across the Health Tech World

    We round up this week's big health tech investment news Do you have an investment story to share with us? Email [email protected] Level Zero Health raises £5.5 million in pre-seed funding UK-based hormone-tracking start-up Level Zero Health has successfully raised $6.9 million (£5.5 million) in pre-seed funding. The figure is the largest raise to date [...]

  • naturalX secures €100 million to accelerate consumer-centred healthcare in Europe

    naturalX Health Ventures has announced a €100 million fund to accelerate consumer-centred healthcare in Europe, becoming the first specialised fund focused exclusively on the intersection of consumer and health in the European market. The fund will focus primarily on Series-A investments while remaining flexible to participate in late Seed and Series-B rounds. Typical first investments [...]

  • Unilabs partners with Oxipit to integrate AI-powered chest X-ray solutions across Europe

    Unilabs, a leading diagnostic services provider in Europe, announced the selection of AI solutions from Oxipit, a pioneering medical imaging AI company, to deploy solutions for chest X-rays throughout Unilabs’ European network. This partnership will see Oxipit’s AI solutions, ChestLink and ChestEye, integrated into Unilabs’ radiology workflows, streamlining chest X-ray reporting through automated triage and [...]

  • Your weekly health tech investment roundup

    We round up the big health tech investment news from the past week Another exciting week in the world of health tech finance, leading with some big news from Monday's Artificial Intelligence (AI) Action Summit in Paris. EU launches InvestAI initiative to mobilise €200 billion of investment in AI On Monday, EU Commission President Ursula [...]

  • Interview: How new €50m global health tech fund aims to speed innovation

    Venture capital firm Nina Capital has launched a €50m fund to invest in health technology startups worldwide. The new fund, its third to date, will focus on supporting founders developing innovative solutions aimed at improving healthcare systems. The third fund from Nina Capital - Fund III - aims to build a new portfolio of investments [...]

  • Biopharma faces lawsuit over documents supporting its US$250m IPO

    Brain disease-focused biopharma Neomora Therapeutics is facing a potential law suit over claims it misled shareholders who took part in its US£250m IPO in 2023. Law firm Robbins LLP is investigating allegations that it misled investors in the offering of documents which supported its IPO. Since the IPO, the value of Neumora common stock has [...]

  • Boost for the sweat sensing tech that could transform – and save – lives globally

    A university spin-out which is pioneering the use of sweat sensors to address the health risks associated with climate change has raised US$26m to expand its global reach. Epicore Biosystems will use the funds to progress its personalised hydration and cloud analytics platform and expand into new biomarker targets relevant to malnutrition and environmental toxin [...]

  • Qureight and Avalyn launch strategic partnership in progressive pulmonary fibrosis

    Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat life-threatening pulmonary diseases, have announced the initiation of a strategic partnership in progressive pulmonary fibrosis. The parnership commences with the ongoing MIST study, a Phase 2b clinical trial evaluating the safety [...]